Paul L Prather

List of Publications by Year
in descending order

41 papers	1,221 citations	516710 16 h-index	361022 35 g-index
41 all docs	41 docs citations	41 times ranked	1252 citing authors

#	Article	IF	Citations
1	Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Î”9-THC: Mechanism underlying greater toxicity?. Life Sciences, 2014, 97, 45-54.	4.3	236
2	Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity. PLoS ONE, 2011, 6, e21917.	2.5	192
3	Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochemical Pharmacology, 2012, 83, 952-961.	4.4	143
4	The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metabolism Reviews, 2014, 46, 72-85.	3.6	102
5	Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicology and Applied Pharmacology, 2013, 269, 100-108.	2.8	78
6	Synthetic Pot: Not Your Grandfatherâ€™s Marijuana. Trends in Pharmacological Sciences, 2017, 38, 257-276.	8.7	78
7	The Endocannabinoid Noladin Ether Acts as a Full Agonist at Human CB2 Cannabinoid Receptors. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 868-875.	2.5	74
8	Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development. Pharmacological Research, 2017, 125, 161-177.	7.1	32
9	Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochemical and Biophysical Research Communications, 2018, 498, 597-602.	2.1	24
10	CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochemical and Biophysical Research Communications, 2013, 441, 339-343.	2.1	21
11	Palmitoylethanolamide Regulates Development of Intestinal Radiation Injury in a Mast Cell-Dependent Manner. Digestive Diseases and Sciences, 2014, 59, 2693-2703.	2.3	21
12	Antinociceptive effects of the 6- O -sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors. Pharmacological Research, 2016, 113, 335-347.	7.1	21
13	Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Frontiers in Pharmacology, 2016, 7, 503.	3.5	20
14	Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Î”9-THC. Frontiers in Pharmacology, 2018, 9, 1084.	3.5	20
15	Inverse Agonists: Tools to Reveal Ligand-Specific Conformations of G Protein-Coupled Receptors. Science Signaling, 2004, 2004, pe1-pe1.	3.6	19
16	The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. British Journal of Pharmacology, 2017, 174, 4523-4539.	5.4	19
17	Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands. ACS Chemical Neuroscience, 2020, 11, 3455-3463.	3.5	15
18	Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacology Biochemistry and Behavior, 2020, 195, 172949.	2.9	15

#	Article	IF	Citations
19	Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. European Journal of Pharmacology, 2014, 737, 140-148.	3.5	13
20	Synthesis, Molecular Pharmacology, and Structureâ€“Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists. Journal of Medicinal Chemistry, 2021, 64, 6381-6396.	6.4	12
21	Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. PLoS ONE, 2016, 11, e0167240.	2.5	10
22	Preface to DMR special edition â€˜Cannabinoid receptors and ligands: therapeutic drug development and abuse potentialâ€™. Drug Metabolism Reviews, 2018, 50, 1-2.	3.6	8
23	The tamoxifen derivative ridaifen-B is a high affinity selective CB 2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicology and Applied Pharmacology, 2018, 353, 31-42.	2.8	8
24	Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity. PLoS ONE, 2015, 10, e0141600.	2.5	7
25	Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. Life Sciences, 2018, 192, 151-159.	4.3	6
26	Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Proteinâ€“Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Î”⁹-Tetrahydrocannabinol and JWH-018. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 259-269.	2.5	4
27	7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127501.	2.2	4
28	Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid Nâ€(adamantanâ€1â€yl)â€1â€(5â€fluoropentyl)â€1Hâ€indoleâ€3â€carboxamide (STSâ€135). Pharmacology Research and Perspectives, 2020, 8, e00561.	2.4	4
29	Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Toxicological Sciences, 2022, 187, 175-185.	3.1	4
30	Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica, 2019, 49, 1388-1395.	1.1	3
31	Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome?. Neuroscience Letters, 2018, 673, 24-27.	2.1	2
32	Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules, 2020, 25, 4820.	3.8	2
33	Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sciences, 2021, 285, 119993.	4.3	1
34	Human UDPâ€glucuronosyltransferases (UGTs) are involved in the metabolism of the natural resveratrol analogues arachidinâ€1, arachidinâ€3 and piceatannol. FASEB Journal, 2010, 24, 967.12.	0.5	1
35	Tolerance and crossâ€tolerance among highâ€efficacy synthetic cannabinoids JWHâ€018 and JWHâ€073 and lowâ€efficacy phytocannabinoid Î” 9 â€THC. FASEB Journal, 2013, 27, 1097.1.	0.5	1
36	Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death. International Journal of Molecular Sciences, 2022, 23, 3049.	4.1	1

#	Article	IF	Citations
37	Major Metabolites of the Synthetic Cannabinoid 5Fâ€ADB Retain High Affinity and Full Efficacy at CB1 Receptors; Potential Mechanism Contributing to Enhanced Toxicity?. FASEB Journal, 2021, 35, .	0.5	0
38	Gambogic acid binds to human CB2 receptors and exhibits potential partial agonist activity. FASEB Journal, 2010, 24, 769.1.	0.5	0
39	The omega and omegaâ€1 monohydroxyl metabolites of the abused K2/Spice synthetic cannabinoids JWHâ€018 and JWHâ€073 bind with high affinity and act as agonists at human cannabinoid 2 receptors (hCB2s). FASEB Journal, 2012, 26, 660.8.	0.5	0
40	Functional consequences of synthetic cannabinoid metabolites and CYP2C9 polymorphisms (838.4). FASEB Journal, 2014, 28, 838.4.	0.5	0
41	In vitro and In vivo Effects of Phase 1 Hydroxylated Metabolites of the Synthetic Cannabinoid ABâ€PINACA [(S)â€Nâ€(1â€aminoâ€3â€methylâ€1â€oxobutanâ€2â€yl)â€1â€pentylâ€1Hâ€indazoleâ€3â€carboxamide]. FASEB Journal, 2015, 29, 825.1.	0.5	0